Castle Biosciences, Inc
Insiders
Last 12 monthsSales planned on beside the trades reported on , and whether each names a .
Planned ·
$13.0M
19 notices · 469,730 sh
Mar 3 to Oct 4
Reported ·
$10.1M
112 sales · 0 buys
Oct 2025 to Jun 2026
The two figures cover different periods.
107 of 112 reported sales carry the 10b5-1 box. Together they are 1.11% of the shares on issue.
under a no plan named▼ salesize is dollars
Form 144 notices, newest first
2026-10-01KRISTEN OELSCHLAGER, Chief Operating Officer$147,556
2026-09-14Tobin Juvenal, Chief Commercial Officer$440,639
2026-09-11Derek Maetzold, Pres. & Chief Exec. Officer$938,023
2026-08-25Tobin Juvenal, Chief Commercial Officer$787,500
2026-08-24Kristen M. Oelschlager, Chief Operating Officer$841,388
2026-08-14Derek Maetzold, Pres. & Chief Exec. Officer$763,959
2026-08-14FRANKLIN M. STOKES, Chief Financial Officer$741,494
2026-07-31Tobin Juvenal, Chief Commercial Officer$630,000
2026-07-31Derek Maetzold, Pres. & Chief Exec. Officer$1,894,536
2026-07-01Derek Maetzold, Pres. & Chief Exec. Officer$589,185
2026-06-16KRISTEN OELSCHLAGER, Chief Operating Officer$617,961
Form 4, 2026-06-18: sold 8,587 at $20.71 Form 4 ↗
2026-06-01Derek Maetzold, Pres. & Chief Exec. Officer$293,748
Form 4, 2026-06-03: sold 9,836 at $20.86 Form 4 ↗
2026-05-07Derek Maetzold, Pres. & Chief Exec. Officer$269,514
Form 4, 2026-05-11: sold 9,836 at $22.15 Form 4 ↗
2026-03-26Derek Maetzold, Pres. & Chief Exec. Officer$449,046
Form 4, 2026-03-30: sold 4,172 at $25.55 Form 4 ↗
2026-03-12Tobin Juvenal, Chief Commercial Officer$528,251
Form 4, 2026-03-16: sold 20,863 at $25.24 Form 4 ↗
2026-03-11Derek Maetzold, Pres. & Chief Exec. Officer$2,461,551
Form 4, 2026-03-13: sold 44,125 at $25.67 Form 4 ↗
2026-03-05FRANKLIN STOKES, Chief Financial Officer$169,048
Form 4, 2026-03-09: sold 6,001 at $27.98 Form 4 ↗
2026-03-05GORDON B. COLE, Director$210,743
Form 4, 2026-03-09: sold 7,403 at $28.47 Form 4 ↗